Few organisations have been able to implement a proactive, risk-based business continuity management programme ensuring them both resilience of their key processes and maximisation of their continuity investments. According to the U.S. National Archives and Records Administration, 93% of companies that lost their data centre for ten days or more due to a disaster filed for bankruptcy within one year of the disaster. Of those businesses that experience a disaster and have no emergency plan, 43% never reopen; of those that do reopen, only 29% are still operating two years later.
The loss of medical technology or on-going research data can be a significant interruption, without even considering the cost of re-running all the tests and validations, if that is even possible.
In addition to these considerations, organisations must be able to prove at all times the quality and integrity of data, even after having just recovered from a serious IT failure, along with a wealth of other regulatory data management constraints.
The loss of key intellectual properties can have an even stronger financial impact on life sciences companies.
This shows the importance of a business continuity programme and/or an IT recovery programme. The key is to be prepared and to know what to do in case of a major incident.
To help life sciences organisations with quality and risk management, Deloitte service offering includes:
Deloitte assists organisations worldwide in improving their resilience against disruption by providing a method of restoring key information and services to an agreed level within an agreed time after the start of the disruption.
Our broad range of experience in evaluating and implementing business continuity management frameworks in Luxembourg and abroad, along with the mature proprietary BCM methodology and tools that have been assisting clients around the world for many years, will support you in implementing a working business continuity solution that is adapted to your specific needs.